Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics was a biopharmaceutical company focused on therapies for allergic and immunologic diseases before becoming a wholly owned subsidiary of BioCryst Pharmaceuticals in 2026. Company news centered on navenibart, also known as STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein in clinical development for hereditary angioedema, and STAR-0310, an investigational monoclonal antibody OX40 antagonist for atopic dermatitis.
Recurring updates covered clinical trial results and scientific meeting presentations, licensing and material agreements, operating and financial results, capital-structure disclosures, governance matters, and shareholder votes tied to Astria's corporate transition.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.